Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals

Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals - Regional Media News

BEIJING, Oct 27 (Reuters) - Jiangsu Hengrui Pharmaceuticals, China's biggest drugmaker by market value, reported on Tuesday a rise of 88.9% in profit for the third quarter of 2026, driven by income from out-licensing deals. • Net profit of 2.5 billion yuan ($375 million) for [...]

China’s Hengrui posts 89% rise in third-quarter net profit, beating estimates

Jiangsu Hengrui Pharmaceuticals, one of China’s largest drug makers, reported a 20.55 per cent rise in third-quarter revenue to 8.95 billion yuan (US$1.34 billion), beating analyst estimates of 8.55 billion yuan amid stronger innovative drug sales. Net profit reached 2.46 billion yuan for the three months ended September 30, jumping 88.92 per cent year on year and exceeding the Bloomberg analyst consensus estimate of 2.38 billion yuan. Improving…

Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals

BEIJING, Oct 27 (Reuters) – Jiangsu Hengrui Pharmaceuticals, China’s biggest drugmaker by market value, reported on Tuesday a rise of 88.9% in profit for the third quarter of 2026, ​driven by income from out-licensing deals. • Net profit of ‌2.5 billion yuan ($375 million) for the quarter ended September 30 was up from 1.3 billion a year ago • The figure beat one analyst’s forecast of about 1.84 billion yuan in net income, LSEG data showed • Thi…

Hengrui Pharmaceuticals Q3 Profit Surges Nearly 90% as Innovative Drugs and Out-Licensing Drive Recovery

A complete, noise free premium China financial news service solution for professionals.